Last reviewed · How we verify
Additional challenge dose
Additional challenge dose is used to stimulate the immune system to produce antibodies against a specific antigen.
Additional challenge dose is used to stimulate the immune system to produce antibodies against a specific antigen. Used for Influenza.
At a glance
| Generic name | Additional challenge dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This is typically done to assess the immune response to a vaccine or to boost immunity in individuals who have not responded adequately to a previous dose. The additional challenge dose is usually administered at a later time point to evaluate the persistence and durability of the immune response.
Approved indications
- Influenza
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Management of Catatonic Features in Adolescents With Profound Autism (NA)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- The TreEat Study- Can Early Introduction of Tree Nuts Prevent Tree Nut Allergy in Infants With Peanut Allergy (PHASE3)
- Characterizing Humoral Immune Response to Mosquito Bites (NA)
- Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans (PHASE1)
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
- Dual Task Training Versus Single Task Training in Chronic Hemiplegic Stroke Patients (NA)
- Sustained Unresponsiveness (SU) to Cashew Nut Protein Following Oral Allergen-Specific Immunotherapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Additional challenge dose CI brief — competitive landscape report
- Additional challenge dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI